This week we will be discussing the KALM-1 trial which was presented at the Late Breaking and High Impact Trial Session at the recently completed #KidneyWk. It was simultaneously published in the NEJM. Kalm-1 investigated whether difelikefalin, a opioid kappa agonist, decreased uremic pruritus.
The Pruritis #NephJC chat wrapup
Pruritus Systematic Review #VisualAbstract
Itching: Another patient commentary
Itching: Patient Commentary
The recent CJASN data from DOPPS, also links to two excellent videos from the NHS Heart of England centre. They are a first person account, giving a vivid example of the change that simple itching can have in all aspects of day to day life.